BeiGene, Ltd.
BGNENext catalyst
Tislelizumab (BGB-A317)
MSI-H/dMMR Solid Tumors
Get an email about BGNE's next catalysts
Track BeiGene (BGNE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 10 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
11 upcoming, 2 past
Tislelizumab (BGB-A317) Phase 2 Est. Readout
Primary completion for Tislelizumab (BGB-A317) trial (NCT03736889) in MSI-H/dMMR Solid Tumors
SourceZanubrutinib Oral Product Phase 2 Est. Readout (MAGNAZ)
Estimated primary completion for Zanubrutinib Oral Product trial (NCT05939037) in Monoclonal Gammopathy of Uncertain Significance. Topline data typically follows completion by weeks to months.
SourceZanubrutinib Pill Phase 2 Est. Readout
Estimated primary completion for Zanubrutinib Pill trial (NCT05650723) in Leukemia, Lymphocytic, Chronic, B-Cell. Topline data typically follows completion by weeks to months.
SourceGlofitamab Phase 2 Est. Readout
Estimated primary completion for Glofitamab trial (NCT07012980) in Diffuse Large B-Cell Lymphoma. Topline data typically follows completion by weeks to months.
SourceBGB-16673 Phase 2 Est. Readout
Estimated primary completion for BGB-16673 trial (NCT05294731) in B-cell Malignancy. Topline data typically follows completion by weeks to months.
SourceGemcitabine Hydrochloride Phase 3 Est. Readout
Primary completion for Gemcitabine Hydrochloride trial (NCT03967977) in Urothelial Carcinoma
SourceTislelizumab Phase 3 Est. Readout
Estimated primary completion for Tislelizumab trial (NCT03967977) in Urothelial Carcinoma. Topline data typically follows completion by weeks to months.
SourceHIPEC Phase 2 Est. Readout
Estimated primary completion for HIPEC trial (NCT06685887) in Gastric Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Adjuvant chemotherapy
Colorectal Cancer
Fluorouracil (5-FU)
Esophageal Squamous Cell Carcinoma (ESCC)
Tislelizumab
Urothelial Carcinoma
Pemetrexed Disodium
Non Small Cell Lung Cancer
5-fluorouracil
Resectable Esophageal Squamous Cell Carcinoma
Pamiparib capsule
Ovarian Cancer
Paclitaxel injection
Non Small Cell Lung Cancer
Cisplatin injection
Non Small Cell Lung Cancer
Zanubrutinib
Refractory Mantle Cell Lymphoma
BGB-3111
Waldenström's Macroglobulinemia
Ociperlimab
Limited Stage Small Cell Lung Cancer
Sonrotoclax
Chronic Lymphocytic Leukemia
Gemcitabine Hydrochloride
Urothelial Carcinoma
BGB-16673
Chronic Lymphocytic Leukemia
BGB-DXP593
Covid19
BGB-290
HER2-negative Breast Cancer
BAT1706
Advanced Hepatocellular Carcinoma
Sitravatinib
Carcinoma, Hepatocellular
Zanidatamab
Breast Cancer
idarubicin/daunorubicin
Acute Myeloid Leukemia
Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1
Esophageal Squamous Cell Carcinoma (ESCC)
HIPEC
Gastric Cancer
Zanubrutinib Pill
Leukemia, Lymphocytic, Chronic, B-Cell
HAIC+TAE
Intrahepatic Cholangiocarcinoma
5-FU
Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma
Alcestobart
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
adjuvant tislelizumab and chemotherapy for MRD+ patients
NSCLC
Mavrostobart (PT199)
Non Small Cell Lung Cancer
PARP Inhibitor BGB-290
IDH1 Mutation
Luteinizing Hormone Releasing Hormone
Prostate Cancer
Zanubrutinib Oral Product
Monoclonal Gammopathy of Uncertain Significance
Glofitamab
Lymphoma, Mantle-Cell
Zanubrutinib Oral Capsule
Lymphoma, Mantle-Cell
BGB-15025
Non-Small Cell Lung Cancer
Fluoropyrimidine (FP)
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Gimistotug
Non-Small Cell Lung Cancer
Obinutuzumab Injection
Leukemia, Lymphocytic, Chronic, B-Cell
Surzebiclimab
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
Immune Checkpoint Inhibitors
Gastric Cancer
SOX
Gastric Cancer
New Hormonal Agent
Prostate Cancer
Concurrent Chemoradiotherapy
Limited Stage Small Cell Lung Cancer
LBL-007
Non-small Cell Lung Cancer
Tislelizumab + Anlotinib
SCLC, Limited Stage
SX-682
Pancreatic Cancer
Tislelizumab (BGB-A317)
MSI-H/dMMR Solid Tumors
BGB-10188
Chronic Lymphocytic Leukemia
BGB-A445
Non-Small Cell Lung Cancer
BGB-A425
Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2
lenvatinib
Advanced Solid Tumor
Supportive Care
COVID-19 Pulmonary Complications
BGB-11417
Mantle Cell Lymphoma
Chemotherapy Doublet
Esophageal Cancer
Fruquintinib
Advanced Solid Tumors
Pamiparib
Brain and Central Nervous System Tumors
Nab paclitaxel
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)
BGB-45035
Rheumatoid Arthritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Adjuvant chemotherapy | Phase 3 | Colorectal Cancer | - | - |
Fluorouracil (5-FU) | Phase 3 | Esophageal Squamous Cell Carcinoma (ESCC) | - | - |
Tislelizumab | Phase 3 | Urothelial Carcinoma | - | - |
Pemetrexed Disodium | Phase 3 | Non Small Cell Lung Cancer | - | - |
5-fluorouracil | Phase 3 | Resectable Esophageal Squamous Cell Carcinoma | - | - |
Pamiparib capsule | Phase 3 | Ovarian Cancer | - | - |
Paclitaxel injection | Phase 3 | Non Small Cell Lung Cancer | - | - |
Cisplatin injection | Phase 3 | Non Small Cell Lung Cancer | - | - |
Zanubrutinib | Phase 3 | Refractory Mantle Cell Lymphoma | - | - |
BGB-3111 | Phase 3 | Waldenström's Macroglobulinemia | - | - |
Ociperlimab | Phase 3 | Limited Stage Small Cell Lung Cancer | - | - |
Sonrotoclax | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Gemcitabine Hydrochloride | Phase 3 | Urothelial Carcinoma | - | - |
BGB-16673 | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
BGB-DXP593 | Phase 2 | Covid19 | - | - |
BGB-290 | Phase 2 | HER2-negative Breast Cancer | - | - |
BAT1706 | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
Sitravatinib | Phase 2 | Carcinoma, Hepatocellular | - | - |
Zanidatamab | Phase 2 | Breast Cancer | - | - |
idarubicin/daunorubicin | Phase 2 | Acute Myeloid Leukemia | - | - |
Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1 | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC) | - | - |
HIPEC | Phase 2 | Gastric Cancer | - | - |
Zanubrutinib Pill | Phase 2 | Leukemia, Lymphocytic, Chronic, B-Cell | - | - |
HAIC+TAE | Phase 2 | Intrahepatic Cholangiocarcinoma | - | - |
5-FU | Phase 2 | Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma | - | - |
Alcestobart | Phase 2 | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | - | - |
adjuvant tislelizumab and chemotherapy for MRD+ patients | Phase 2 | NSCLC | - | - |
Mavrostobart (PT199) | Phase 2 | Non Small Cell Lung Cancer | - | - |
PARP Inhibitor BGB-290 | Phase 2 | IDH1 Mutation | - | - |
Luteinizing Hormone Releasing Hormone | Phase 2 | Prostate Cancer | - | - |
Zanubrutinib Oral Product | Phase 2 | Monoclonal Gammopathy of Uncertain Significance | - | - |
Glofitamab | Phase 2 | Lymphoma, Mantle-Cell | - | - |
Zanubrutinib Oral Capsule | Phase 2 | Lymphoma, Mantle-Cell | - | - |
BGB-15025 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Fluoropyrimidine (FP) | Phase 2 | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | - | - |
Gimistotug | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Obinutuzumab Injection | Phase 2 | Leukemia, Lymphocytic, Chronic, B-Cell | - | - |
Surzebiclimab | Phase 2 | Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in | - | - |
Immune Checkpoint Inhibitors | Phase 2 | Gastric Cancer | - | - |
SOX | Phase 2 | Gastric Cancer | - | - |
New Hormonal Agent | Phase 2 | Prostate Cancer | - | - |
Concurrent Chemoradiotherapy | Phase 2 | Limited Stage Small Cell Lung Cancer | - | - |
LBL-007 | Phase 2 | Non-small Cell Lung Cancer | - | - |
Tislelizumab + Anlotinib | Phase 2 | SCLC, Limited Stage | - | - |
SX-682 | Phase 2 | Pancreatic Cancer | - | - |
Tislelizumab (BGB-A317) | Phase 2 | MSI-H/dMMR Solid Tumors | - | - |
BGB-10188 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
BGB-A445 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BGB-A425 | Phase 2 | Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2 | - | - |
lenvatinib | Phase 2 | Advanced Solid Tumor | - | - |
Supportive Care | Phase 2 | COVID-19 Pulmonary Complications | - | - |
BGB-11417 | Phase 2 | Mantle Cell Lymphoma | - | - |
Chemotherapy Doublet | Phase 2 | Esophageal Cancer | - | - |
Fruquintinib | Phase 2 | Advanced Solid Tumors | - | - |
Pamiparib | Phase 2 | Brain and Central Nervous System Tumors | - | - |
Nab paclitaxel | Phase 2 | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC) | - | - |
BGB-45035 | Phase 2 | Rheumatoid Arthritis | - | - |
Frequently asked questions
What is in BeiGene, Ltd.'s drug pipeline?→
CatalystAlert tracks 57 drug candidates in BeiGene, Ltd.'s (BGNE) pipeline across Phase 3, Phase 2. Its lead program is Tislelizumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BeiGene, Ltd.'s next FDA catalyst?→
BeiGene, Ltd.'s (BGNE) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BGNE biotech catalysts?→
Add BGNE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BeiGene, Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.